Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Environmental / Social category.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fate Therapeutics Inc. faces significant business risks related to the privacy of personal information, including health data utilized in product development and clinical trials. The company must navigate a complex landscape of federal, state, and international data protection laws, such as HIPAA, CCPA, EU GDPR, and UK GDPR, which impose strict requirements on data handling and security. Non-compliance could result in substantial fines, legal actions, and reputational damage, necessitating considerable resources to ensure adherence to these regulations. Furthermore, the evolving nature of privacy laws and potential data breaches pose ongoing challenges that could materially impact the company’s operations and financial standing.
Overall, Wall Street has a Moderate Buy consensus rating on FATE stock based on 5 Buys and 3 Holds.
To learn more about Fate Therapeutics Inc’s risk factors, click here.